Neisseria gonorrhoeae (N. gonorrhoeae) outer membrane protein reduction modifiable protein (Rmp) has strong immunogenicity. However, anti-Rmp antibodies block rather than preserve the antibacterial effects of protective antibodies, which hampers the development of vaccines for gonococcal infections. We herein constructed an Rmp deletion mutant strain of N. gonorrhoeae by gene homologous recombination. The 261–460 nucleotide residues of Rmp gene amplified from N. gonorrhoeae WHO-A strain were replaced with a kanamycin-resistant Kan gene amplified from pET-28a. The resultant hybridized DNA was transformed into N. gonorrhoeae WHO-A strain. PCR was used to screen the colonies in which wild-type Rmp gene was replaced with a mutant gene fragment. Western blotting revealed that the Rmp deletion mutant strain did not express Rmp protein. Rmp deletion did not alter the morphological and Gram staining properties of the mutant strain that grew slightly more slowly than the wild-type one. Rmp gene mutated stably throughout 25 generations of passage. Antibody-mediated complement-dependent cytotoxicity assay indicated that the antibodies induced by the mutant strain had evidently higher bactericidal activities than those induced by the wild-type strain. Further modification of the Rmp deletion mutant strain is still required in the development of novel live attenuated vaccines for gonorrhea by Opa genes deletion or screening of phenotypic variant strains that do not express Opa proteins.
References
[1]
World Health Organization (2012) Global incidence and prevalence of selected curable sexually transmitted infections – 2008. Geneva, Switzerland.
[2]
De Seta F, Banco R, Turrisi A, Airoud M, De Leo R, et al. (2012) Pelvic inflammatory disease (PID) from Chlamydia trachomatis versus PID from Neisseria gonorrhea: from clinical suspicion to therapy. G Ital Dermatol Venereol 147: 423–430.
[3]
Centers for Disease Control and Prevention (CDC) (2007) Increases in gonorrhea-eight western states, 2000–2005. MMWR Morb Mortal Wkly Rep 56: 222–225.
[4]
Ding J, Rapista A, Teleshova N, Mosoyan G, Jarvis GA, et al. (2010) Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation. J Immunol 184: 2814–2824. doi: 10.4049/jimmunol.0902125
[5]
Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, et al. (2008) Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 180: 6176–6185. doi: 10.4049/jimmunol.180.9.6176
[6]
Centers for Disease Control and Prevention (CDC) (2012) Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61: 590–594. doi: 10.1016/j.annemergmed.2012.10.014
[7]
Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, et al. (2011) Vaccines for gonorrhea: can we rise to the challenge? Front Microbiol 2: 124. doi: 10.3389/fmicb.2011.00124
[8]
Siegel M, Olsen D, Critchlow C, Buchanan TM (1982) Gonococcal pili: safety and immunogenicity in humans and antibody function in vitro. J Infect Dis 145: 300–310. doi: 10.1093/infdis/145.3.300
[9]
Tramont EC, Sadoff JC, Boslego JW, Ciak J, McChesney D, et al. (1981) Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment. J Clin Invest 68: 881–888. doi: 10.1172/jci110343
[10]
McChesney D, Tramont EC, Boslego JW, Ciak J, Sadoff J, et al. (1982) Genital antibody response to a parenteral gonococcal pilus vaccine. Infect Immun 36: 1006–1012. doi: 10.1016/0264-410x(91)90147-x
[11]
Boslego JW, Tramont EC, Chung RC, McChesney DG, Ciak J, et al. (1991) Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9: 154–162. doi: 10.1016/0264-410x(91)90147-x
[12]
Hansen JK, Demick KP, Mansfield JM, Forest KT (2007) Conserved regions from Neisseria gonorrhoeae pilin are immunosilent and not immunosuppressive. Infect Immun 75: 4138–4147. doi: 10.1128/iai.02015-06
[13]
Brossay L, Paradis G, Pépin A, Mourad W, Coté L, et al. (1993) Idiotype and anti-anti-idiotype antibodies to Neisseria gonorrhoeae lipooligosaccharides with bactericidal activity but no cross-reactivity with red blood cell antigens. J Immunol 151: 234–243.
[14]
Gulati S, McQuillen DP, Sharon J, Rice PA (1996) Experimental immunization with a monoclonal anti-idiotope antibody that mimics the Neisseria gonorrhoeae lipooligosaccharide epitope 2C7. J Infect Dis 174: 1238–1248. doi: 10.1093/infdis/174.6.1238
[15]
Ngampasutadol J, Rice PA, Walsh MT, Gulati S (2006) Characterization of a peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria gonorrhoeae and resultant immune responses and function. Vaccine 24: 157–170. doi: 10.1016/j.vaccine.2005.07.065
[16]
Cole JG, Jerse AE (2009) Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops. PLoS One 4: e8108. doi: 10.1371/journal.pone.0008108
[17]
Heckels JE, Virji M, Tinsley CR (1990) Vaccination against gonorrhoea: the potential protective effect of immunization with a synthetic peptide containing a conserved epitope of gonococcal outer membrane protein IB. Vaccine 8: 225–230. doi: 10.1016/0264-410x(90)90050-v
[18]
Zhu W, Thomas CE, Sparling PF (2004) DNA immunization of mice with a plasmid encoding Neisseria gonorrhea PorB protein by intramuscular injection and epidermal particle bombardment. Vaccine 22: 660–669. doi: 10.1016/j.vaccine.2003.08.036
[19]
Zhu W, Thomas CE, Chen CJ, Van Dam CN, Johnston RE, et al. (2005) Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles. Infect Immun 73: 7558–7568. doi: 10.1128/iai.73.11.7558-7568.2005
[20]
Price GA, Russell MW, Cornelissen CN (2005) Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun 73: 3945–3953. doi: 10.1128/iai.73.7.3945-3953.2005
[21]
Thomas CE, Zhu W, Van Dam CN, Davis NL, Johnston RE, et al. (2006) Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles. Infect Immun 74: 1612–1620. doi: 10.1128/iai.74.3.1612-1620.2006
[22]
Plante M, Cadieux N, Rioux CR, Hamel J, Brodeur BR, et al. (1999) Antigenic and molecular conservation of the gonococcal NspA protein. Infect Immun 67: 2855–2861.
[23]
Li G, Jiao H, Jiang G, Wang J, Zhu L, et al. (2011) Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice. Clin Vaccine Immunol 18: 1817–1822. doi: 10.1128/cvi.05245-11
[24]
Barh D, Kumar A (2009) In silico identification of candidate drug and vaccine targets from various pathways in Neisseria gonorrhoeae. In Silico Biol 9: 225–231.
[25]
Plante M, Jerse A, Hamel J, Couture F, Rioux CR (2000) Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae. J Infect Dis 182: 848–855. doi: 10.1086/315801
[26]
Lytton EJ, Blake MS (1986) Isolation and partial characterization of the reduction-modifiable protein of Neisseria gonorrhoeae.. J Exp Med 164: 1749–1759. doi: 10.1084/jem.164.5.1749
[27]
Judd RC (1982) 125I-Peptide mapping of protein III isolated from four strains of Neisseria gonorrhoeae. Infect Immun 37: 622–631.
[28]
Wong TP, Johnston KH (1981) One-dimensional peptide mapping of the major outer membrane protein of Neisseria gonorrhoeae. Infect Immun 34: 739–745.
[29]
Gotschlich EC, Blake MS, Koomey JM, Seiff M, Derman A (1986) Cloning of the structural genes of three H8 antigens and of protein III of Neisseria gonorrhoeae. J Exp Med 164: 868–81. doi: 10.1084/jem.164.3.868
[30]
Gotschlich EC, Seiff M, Blake MS (1987) The DNA sequence of the structural gene of gonococcal protein III and the flanking region containing a repetitive sequence. Homology of protein III with enterobacterial OmpA proteins. J Exp Med 165: 471–82. doi: 10.1084/jem.165.2.471
[31]
McDade RL, Johnston KH (1980) Characterization of serologically dominant outer membrane proteins of Neisseria gonorrhoeae. J Bacteriol 141: 1183–1191.
[32]
Rice PA, Vayo HE, Tam MR, Blake MS (1986) Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp MED 164: 1735–1748. doi: 10.1084/jem.164.5.1735
[33]
Plummer FA, Chubb H, Simonsen JN, Bosire M, Slaney L, et al. (1993) Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection. J Clin Invest 91: 339–43. doi: 10.1172/jci116190
[34]
Wetzler LM, Gotschlich EC, Blake MS, Koomey JM (1989) The construction and characterization of Neisseria gonorrhoeae lacking protein III in its outer membrane. J Exp Med 169: 2199–209. doi: 10.1084/jem.169.6.2199
[35]
Cartwright CP, Stock F, Gill VJ (1994) Improved enrichment broth for cultivation of fastidious organisms. J Clin Microbiol 32: 1825–1826.
[36]
Takei M, Yamaguchi Y, Fukuda H, Yasuda M, Deguchi T (2005) Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. J Clin Microbiol 43: 4321–4327. doi: 10.1128/jcm.43.9.4321-4327.2005
[37]
Rice PA, McQuillen DP, Gulati S, Jani DB, Wetzler LM, et al. (1994) Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection? Ann N Y Acad Sci 730: 7–14. doi: 10.1111/j.1749-6632.1994.tb44234.x
[38]
Chen CC, Hsia KC, Huang CT, Wong WW, Yen MY, et al. (2011) Draft Genome Sequence of a Dominant, Multidrug-Resistant Neisseria gonorrhoeae Strain, TCDC-NG08107, from a Sexual Group at High Risk of Acquiring Human Immunodeficiency Virus Infection and Syphilis. J Bacteriol 193: 1788–1789. doi: 10.1128/jb.00007-11
[39]
Chung GT, Yoo JS, Oh HB, Lee YS, Cha SH, et al. (2008) Complete genome sequence of Neisseria gonorrhoeae NCCP11945. . J. Bacteriol. 190: 6035–6036. doi: 10.1128/jb.00566-08
[40]
Pantelic M, Kim YJ, Bolland S, Chen I, Shively J, et al. (2005) Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production. Infect Immun 73: 4171–4179. doi: 10.1128/iai.73.7.4171-4179.2005
[41]
Boulton IC, Gray-Owen SD (2002) Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat Immunol 3: 229–236. doi: 10.1038/ni769
[42]
Voges M, Bachmann V, Kammerer R, Gophna U, Hauck CR (2010) CEACAM1 recognition by bacterial pathogens is species-specific. BMC Microbiol 10: 117. doi: 10.1186/1471-2180-10-117
